Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Awakn

EXCLUSIVE: New Partnership Brings Leading Psychedelic Protocol For Alcoholism Treatment To NYC

NYC-based clinics brand Nushama has partnered with Awakn Life Sciences (OTCQB: AWKNF), a clinical-stage psychedelics biotech company to bring

Can Ketamine Treat Alcohol Addiction? In-Clinic Therapy Vs. Retreats

Can Ketamine Treat Alcohol Addiction? In-Clinic Therapy Vs. Retreats

(Part four of a four-part series - Read part three)

Can Ketamine Treat Alcohol Addiction? The Awakn Approach

Can Ketamine Treat Alcohol Addiction? The Awakn Approach

(Part three of a four-part series)

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Battling With Booze? Here's A Deeper Look At Ketamine for Alcohol Use Disorder

This article by Elisabetta Fato was originally published on Microdose and appears here with permission. In the last decades, there has been a growing interest in psychedelics for the treatment of mood and behavioral disorders, among which are substance use disorders.

Phase 3 Trial On Ketamine Therapy Gets Almost $2M From UK State Funding

Biotech psychedelics company Awakn Life Sciences Corp. (OTCQB: AWKNF) has been granted funding for 66% of the costs from its phase 3 clinical trial on

UK To Fund Development Of Awakn's Ketamine-Assisted Therapy Program For Alcohol Use Disorder In US And UK

Biotech therapeutics company Awakn Life Sciences Corp.

Awakn's Study On Psychedelics For Treating Addiction Shows Promise, Will Undertake Broader Research

Awakn Life Sciences (OTCQB: AWKNF) has announced the successful completion of the first ketamine study for a varied set of behavioral addictions.

inkl

Read news from The Economist, FT, and more,
with one subscription

Is The UK Becoming A Global Center For Psychedelic Medicine?

Is The UK Becoming A Global Center For Psychedelic Medicine?

This article by Freddie Earlam was originally published on Microdose and appears here with permission. If the industry-defining research already conducted at UK centers such as Imperial College, King’s college or even Exeter University’s recent Ketamine Research isn’t enough to convince you, then two more crucial factors surely will. Firstly, a new ‘accelerated pathway’ has…

Stifel Initiates Coverage On Awakn Life Sciences With A Speculative Buy, $8 Target Price Target

Stifel Initiates Coverage On Awakn Life Sciences With A Speculative Buy, $8 Target Price Target

Awakn Life Sciences (OTC: AWKNF) is in the news after a respected analyst has upgraded the stock. Awakn is a publicly traded company which trades on the over-the-counter market with the symbol of

Top 5 Most Influential Psychedelic Studies

Top 5 Most Influential Psychedelic Studies

This article was originally published on Psychedelic Spotlight and appears here with permission. While psychedelic studies now number in the thousands since Western research began in the 1950s, we unpack five of the most important in recent years as psychedelics are on the cusp of becoming mainstream medicines. When it…

Awakn Life Sciences Seeks To Treat Addictions: Gambling, Binge Eating And Compulsive Sexual Behavior

Awakn Life Sciences Seeks To Treat Addictions: Gambling, Binge Eating And Compulsive Sexual Behavior

Awakn Life Sciences (OTC: AWKNF) is not only going after alcoholism but also binge eating disorder, compulsive sexual behavior and even Internet gaming disorder.

As Australia legalises MDMA and psilocybin for medical use, we go inside one London psychedelics clinic

As Australia legalises MDMA and psilocybin for medical use, we go inside one London psychedelics clinic

Psychedelics are being touted as a cure for depression, addiction and PTSD — but will this new industry live up to the hype? As the Australian government announces that it will legalise MDMA and magic mushrooms for medical use, Alexandra Jones visits London’s first clinic to find out whether the…

Evening Standard

Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS

Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS

New Awakn Study Shows Ketamine Has Potential To Treat Alcoholism

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

University of Exeter

Compass Pathways

Imperial College

Exeter University

Psychedelic Spotlight

Awakn Life Sciences

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

397,269 stories

144,265 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play